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Abstract: 
 
We present the updated British Association for Sexual Health and HIV guidelines for HIV post-
exposure prophylaxis following sexual exposure (PEPSE). This document includes a review of the 
current data to support the use of PEPSE, considers how to calculate the risks of infection after a 
potential exposure, and provides recommendations on when PEPSE should and should not be 
considered. We also review which medications to use for PEPSE, provide a checklist for initial 
assessment and make recommendations for monitoring individuals receiving PEPSE. Special 
scenarios, cost-effectiveness of PEPSE and issues relating to service provision are also discussed. 
Throughout the document, the place of PEPSE within the broader context of other HIV prevention 
strategies is considered. 
 
 
Keywords: 
 
Post-exposure prophylaxis (PEP), sexual exposure, HIV prevention, BASHH guidelines, 
antiretroviral therapy  
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New in the 2015 guidelines: 
 
1. PEPSE is not routinely recommended after any type of sex with HIV-positive source 
on antiretroviral therapy (ART) with a confirmed and sustained (>6 months) 
undetectable plasma HIV viral load (<200c/ml). 
  
2. Initiation of PEPSE is recommended as soon as possible after exposure, preferably 
within 24 hours of exposure but can be offered up to 72 hours. 
 
3. The first-line regimen is Truvada and raltegravir.  
 
4. Routine blood test monitoring is not recommended for raltegravir-based PEP with 
normal baseline blood tests, unless clinically indicated. 
 
5. Follow-up HIV testing is recommended 8-12 weeks after exposure. 
 
6. It is acceptable to provide the full 28-day course of PEPSE on first visit to a 
specialist clinic provided the recipient has met with a Sexual Health Adviser, source 
testing is not possible and there are no clinical or adherence concerns. 
 
7. PEPSE is an emergency method of HIV prevention and should not be considered or 
encouraged as a method of first resort.  Other evidence-based HIV prevention 
methods should be discussed. 
 
8. If further risk occurs during the last two days of the PEPSE course, then PEPSE 
should be continued for 48 hours after the last high-risk sexual exposure. 
 
9. In the event of a new HIV diagnosis after initiation of PEP, PEP should be continued 
pending discussion with an HIV specialist. Long-term ART may be beneficial in the 
setting of primary HIV infection. 
 
10. If the recipient has missed more than 48 hours of PEPSE then the course should be 
discontinued.  
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Summary of recommendations: 
 
When to use PEPSE? 
 
We recommend the use of PEPSE where there is a significant risk of HIV transmission (risk 
>1/1000), see Table 3 (1C).  
 
If the source is of unknown status: 
 We suggest proactive attempts are made to establish the HIV status of the source (2C).  
 
Source individual known to be HIV-positive:  
 Attempts should be made at the earliest opportunity to determine the HIV viral load, 
resistance profile and treatment history (1D).  
 PEPSE is no longer recommended if the source is on antiretroviral therapy (ART) with a 
confirmed and sustained (>6 months) undetectable plasma HIV viral load (<200c/ml) (1B). 
However, if there are any doubts about the HIV viral load history or the source’s adherence 
to ART then PEP should be given following unprotected receptive anal intercourse.  
 Individuals should be encouraged to attend for formal PEP assessment and verification of 
source’s HIV details even when they believe the source has an undetectable HIV viral load 
(GPP).  
 If drug resistance is suspected in the source the regimen should be tailored accordingly 
following discussion with an HIV physician (1D).  
 
What to use for PEPSE? 
 
We recommend the use of Truvada and raltegravir as the regimen of choice for PEPSE (1B). See 
Table 4 for alternatives regimens and Appendix A for interactions.  
 
We recommend that an accurate medication history should be taken, including the use of over the 
counter medication, vitamins/minerals, herbal remedies and recreational drugs before PEPSE is 
prescribed (1D).  
 
How to use PEPSE? 
 
We recommend PEPSE should be initiated as soon as possible after exposure, preferably within 24 
hours, but can be considered up to 72 hours (1D).  
 
We do not recommend giving PEPSE beyond 72 hours (1D).  
 
We recommend that the duration of PEPSE should be 28 days (1D).  
 
PEPSE should not be considered or encouraged as a first-line method of HIV prevention. Other 
more evidence-based methods should be discussed (1C). 
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We recommended that all individuals attending for PEP be strongly encouraged to meet with an 
appropriate health care professional competent in sexual health advising to discuss risk reduction.  
Provision of PEPSE should be fully integrated into counselling around safer sex strategies (1C).  
 
We suggest individuals seeking PEPSE should be encouraged to attend for future regular sexual 
health check-ups (2C). 
 
We recommend that an accurate medication history should be obtained, including use of over the 
counter medications, vitamins/minerals, herbal remedies and recreational drugs before PEPSE is 
prescribed (1D).  
 
We suggest routine blood test monitoring after initiation of raltegravir-based PEPSE is not 
necessary unless clinically indicated or if baseline blood tests are abnormal (2C). 
 
We suggest performing an STI screen at baseline as indicated, as well as at 2 weeks post-exposure 
(2C).  
 
We recommend follow-up HIV testing at 8-12 weeks after exposure (1C).  
 
We recommend using a 4th generation laboratory venous blood HIV test at baseline and for follow-
up testing (1D).  
 
We suggest offering an ultra-rapid course of Hepatitis B vaccination if clinically indicated and the 
individual has no immunity at baseline (GPP). 
 
We recommend pregnancy testing in women considering PEPSE (1D). We suggest pregnancy 
should not alter the decision to start PEPSE (2D). Women must be counselled that antiretroviral 
agents used for PEPSE are unlicensed in pregnancy and risks / benefits must be carefully 
discussed (1D).  
 
In the event of a further high-risk sexual exposure in the last two days of the PEPSE course the 
PEP should be continued for 48 hours after the last high-risk exposure (2B). 
 
Individuals experiencing a skin rash or flu-like illness during or after taking PEPSE should be 
advised to attend for urgent review to exclude an HIV seroconversion illness (2D).  
 
If the HIV test is positive after PEPSE has already been initiated we recommend continuing PEPSE 
pending review by an HIV specialist (GPP).  
 
For PEPSE to be maximally effective 24-hour availability is recommended (1C). This should include 
out of hours expert advice if required (1D). 
 
Information about PEPSE should be included when counselling individuals at risk of acquiring HIV 
infection as well as those already diagnosed with HIV infection (2D).  
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1. Objectives: 
 
We aim to provide evidence-based recommendations for the most appropriate use of HIV post-
exposure prophylaxis following sexual exposure (PEPSE). The aim of PEPSE is to prevent HIV 
transmission. Risk of transmission, timing of PEP, preferred regimen, drug-drug interactions, follow-
up, risk reduction and special scenarios are discussed. Consideration is given to the role of PEPSE 
within the broader context of HIV prevention and sexual health.  
 
The guideline is intended to be complementary to existing Department of Health and Expert 
Advisory Group on AIDS (EAGA) guidance on PEP (1). It is aimed primarily at clinicians and policy-
makers in sexual health, sexual assault referral centres (SARCs), and primary and emergency care 
providers within the UK who should consider the development of appropriate local pathways. It is 
likely that this guideline will also be used for information provision by voluntary sector agencies to 
provide information for individuals.  
 
The recommendations are aimed primarily at individuals aged 16 or older and may not be 
appropriate for use in all situations, including occupational exposures. Decisions to follow these 
recommendations must be based on the professional judgment of the clinician and consideration of 
individual patient circumstances and available resources. 
 
2. Methods: 
 
The multidisciplinary guideline-working group developed the guidelines based on processes 
outlined in the BASHH Framework for Guideline Development (2). The guideline is based on a 
comprehensive literature review on PEPSE and HIV transmission. All members underwent GRADE 
training. The recommendations are the result of a series of face-to-face and virtual meetings of the 
Writing Committee and will incorporate input from the public consultation process. 
 
PICO questions were set as: 
POPULATIONS: sexual, non-occupational, bite exposure to HIV 
INTERVENTION: post-exposure prophylaxis, PEP, PEPSE, antiretroviral therapy 
COMPARISON: no intervention, ART treatment as prevention (TasP), condoms, pre-exposure 
prophylaxis (PrEP) 
OUTCOME: HIV infection, seroconversion, toxicity, completion, sexual behavior, cost-effectiveness 
 
2.1 Search strategy: 
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Current British Association for Sexual Health and HIV (3), USA Centers for Disease Control and 
Prevention (4), World Health Organisation (5) and Australian Society of HIV Medicine guidelines 
were reviewed (6).  
 
Medline, Embase, Cochrane Library were searched from January 1990 to November 2014 for all 
articles relating to HIV post-exposure prophylaxis (985 abstracts reviewed). Search terms were HIV 
AND post-exposure prophylaxis, PEP, PEPSE, non-occupational, sexual, antiretroviral, 
chemoprophylaxis. A second search from 2008 to November 2014 was conducted for HIV 
transmission (2493 abstracts reviewed). Search terms were HIV AND transmission AND risk / risk 
reduction. Conference abstracts from Conference on Retroviruses and Opportunistic Infection, 
World AIDS, Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), HIV 
Drug Therapy from January 2012 to November 2014 were reviewed.  
 
Restrictions: English language papers.  
 
2.2 Stakeholder involvement, piloting and feedback: 
The guideline-working group included representatives from the British Association for Sexual Health 
and HIV (BASHH), British HIV Association (BHIVA), EAGA, Society of Sexual Health Advisers 
(SSHA), HIV Pharmacy Association (HIVPA), the Terrence Higgins Trust (THT) and the National 
AIDS Trust (NAT). Patients’ perspectives were considered by involvement of THT and NAT, 
reviewing the literature for information from patient surveys and the public consultation process.   
 
3. Background:  
Pathogenesis studies indicate that there may be a window of opportunity to avert HIV infection by 
inhibiting viral replication following an exposure. Once HIV crosses a mucosal barrier it may take up 
to 48–72 hours before HIV can be detected within regional lymph nodes and up to five days before 
HIV can be detected in blood (7, 8). Initiation of antiretroviral therapy (ART) has been shown to 
reduce dissemination and replication of virus in all tissues if initiated early after inoculation in an 
animal model (9).  
 
4. Risk of HIV transmission: 
The probability of HIV transmission depends upon the exposure characteristics, the infectivity of the 
source and host susceptibility.  Where individuals have multiple exposures within 72 hours a 
cumulative risk should be considered. 
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Table 1 shows the estimated HIV prevalence (including both diagnosed and undiagnosed infection) 
in adults aged over 15-59 years in the UK in 2014. HIV prevalence in other countries can be found 
in the UNAIDS 2014 Gap report: 
 http://www.unaids.org/en/resources/campaigns/2014/2014gapreport/gapreport 
 
The risk of HIV transmission per exposure from a known HIV-positive individual not on ART is 
summarized in table 2. These figures are estimates that have been deduced from cohort and 
modeling studies.  
 
The risk of an individual acquiring HIV following an exposure can be calculated by multiplying the 
risk that the source is HIV-positive (Table 1) and the risk per exposure (Table 2):  
 
 
 
For example, if a man presents for PEPSE following unprotected receptive anal intercourse with 
ejaculation with male partner of unknown HIV status in London:  
Risk of HIV transmission = 12.5/100  x  1/65  =  12.5/6500  =  1/520 
 
However, certain factors may increase the risk of HIV transmission and must be considered and 
discussed in a PEP consultation, see box 1: 
 
5. Data supporting the use of PEP against HIV:  
5.1 Animal studies 
Animal studies suggest that PEP can be potentially effective and that time to initiation and duration 
are important. Animal studies are not standardised and use different retroviruses, size of inocula 
and modes of administration; this may, at least in part, explain their differing results.  
 
Two studies demonstrated effectiveness of subcutaneous PMPA (tenofovir) in macaque models 
following intravenous SIV (46) or intravaginal HIV-2 inoculation (47); efficacy was highest if PEP 
was administered within 24-36 hours and continued for 28 days. In another macaque study, oral 
zidovudine, lamivudine and indinavir offered no protection following intravenous exposure (48), 
though this may have been due to inoculation mode and/or size. The same group demonstrated that 
higher dose oral PEP was effective following intravaginal exposure highlighting the importance of 
achieving adequate drug concentrations (49). 
 
More recent animal studies have demonstrated effectiveness of intermittent pre-exposure 
Risk of HIV transmission = risk that source is HIV positive  x  risk per exposure 
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prophylaxis (PrEP) and PEP using oral Truvada (tenofovir and emtricitabine) in macaques following 
rectal inoculation. The highest level of protection was achieved with a first dose 22 hours to seven 
days prior to the exposure and a second dose two hours after the exposure (50). 
 
5.2 Human studies 
Prospective randomized controlled trials (RCTs) to determine the efficacy of PEPSE have not been 
performed and are not feasible due to the ethics of withholding a potentially efficacious treatment 
and the difficulty in recruiting a sufficient sample size.  
 
a) Occupational exposure to HIV 
A retrospective case-controlled study among health-care workers occupationally exposed to HIV 
infection demonstrated that a 28-day course of zidovudine was protective, odds ratio (OR) 0.19 
(95% confidence interval (CI) 0.06–0.52%) (29). However there are also instances where PEP has 
failed to prevent HIV infection following occupational exposure (51). 
 
b) Vertical transmission 
In a subset of women in the AIDS Clinical Trials Group (ACTG) 076 study who did not receive 
zidovudine prior to delivery but where the neonate was given a six-week course of zidovudine, 
initiated within 48 hours of delivery, a protective effect was observed (52, 53).  
 
c) Sexual exposure to HIV 
No prospective RCTs to determine the efficacy of PEPSE were identified. Two observational 
PEPSE studies undertaken in Brazil, one among MSM and another in women following sexual 
assault, demonstrated that fewer HIV seroconversions in individuals receiving PEPSE compared 
with those who did not. However, neither study was powered to detect a difference in HIV incidence 
(54).  
 
6. Factors influencing the efficacy of PEP: 
PEP is not considered 100% effective, as there have been cases of HIV acquisition whilst on PEP. 
These may be related to: 
o Delayed initiation (29, 46)  
o Transmission of resistant virus 
o Variable genital tract drug penetration  
o Poor/non-adherence 
o Further high risk sexual exposures 
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Baseline HIV resistance recorded on the UK HIV Drug Resistance Database is declining amongst 
MSM in the UK (7.2%, in 2013) but is stable amongst heterosexuals (6.0% in 2013).  No baseline 
integrase resistance has been detected in the national database but the data is limited (120 tests 
2010-2012). Integrase-experienced patients demonstrate stable levels of resistance at 15% of those 
tested, though rates may be higher in other countries (55). If drug resistance is suspected in the 
source the regimen should be tailored accordingly following discussion with an HIV physician (1C). 
 
Poor adherence was a risk for subsequent seroconversion in a retrospective analysis of PEPSE 
failures (56). A recent case-series of 19 HIV diagnoses after PEPSE initiation found that one was a 
chemoprophylactic failure related to suboptimal dosing of Kaletra in the first week of treatment; the 
other 18 had primary HIV at baseline (57). Worryingly PEP completion rates to 28-days have been 
historically poor in the UK (range 42-82%) (58-67).  
 
7. Possible risks of PEPSE: 
7.1 Safety 
The possibility of side effects and both short and potential long-term toxicities must be balanced 
with the potential benefit of PEP. This has been considered when determining risk thresholds for 
recommending PEPSE.   
 
7.2 Behavioural implications: 
Historically there were concerns that PEPSE availability would reduce commitment to other 
prevention strategies. However several studies have demonstrated a reduction in self-reported risk 
behaviour: a Brazilian MSM cohort (54) and two San Francisco clinics providing PEPSE to MSM 
(68). PEP awareness had no effect on condom use by serodiscordant couples in a cross-sectional 
survey (69). 
 
Conversely, some authors have argued that health-related interventions such as PEPSE may 
actually provide benefit by capitialising on ‘close calls’ to motivate and sustain risk reduction in 
individuals who have engaged in risk behavior (70). 
 
7.3 Acute anxiety 
The decision to administer PEPSE should be based on the risk of HIV acquisition and not to 
manage a state of acute anxiety following a sexual exposure. Referral for psychological support for 
individuals reporting anxiety related to the risk of HIV transmission may be beneficial (2D). 
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8. Comparison with other HIV prevention strategies: 
 
The Writing Committee believes it is crucial to consider PEPSE as only one strategy for preventing 
HIV infection and must be considered within the broader context of HIV prevention. Other methods 
of HIV prevention have a more robust evidence base and as such PEPSE should not be considered 
or encouraged as a first line method of HIV prevention (1C). Alternative methods of HIV prevention 
and their respective effectiveness are summarized in the BHIVA/BASHH position statement on HIV 
Pre-exposure Prophylaxis and should be used to aid discussion of the options available to service 
users (71): http://www.bhiva.org/documents/Publications/PrEP2012.pdf. Condoms are highly 
protective, although use is inconsistent (12, 72). Data in support of treatment of HIV-positive 
partners as a prevention strategy is strong (13, 14). 
 
The Writing Committee anticipates that, pending results of discussions at the time of guideline 
development, the repertoire of prevention tools will expand to include pre-exposure prophylaxis 
(PrEP); individuals presenting for PEPSE may be candidates for PrEP when it becomes available. 
 
9. Recommendations for prescribing PEPSE: 
 
A risk-benefit analysis should be undertaken for every individual presenting following an exposure 
and the decision to initiate PEPSE made on a case-by-case basis. This should consider both the 
risk of the source being HIV-positive (Table 1), the risk of transmission according to exposure 
(Table 2) and as well as the viral load in the source, if known. The recommendations are 
summarised in Table 3. Awareness of the local HIV seroprevalence in the potential source should 
be factored into local protocols. 
 
The Writing Committee suggests using the following threshold to determine if PEPSE is indicated: 
o Transmission risk is greater than 1 in 1000  - PEPSE is recommended (2D).  
o Transmission risk is between 1 in 1000 and 1 in 10,000 - PEPSE may be considered 
We recommend the use of PEPSE where there is a significant risk of HIV 
transmission (1C) 
PEPSE should not be considered or encouraged as a first line method of HIV 
prevention (1C) 
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(2D). The Writing Committee feels that when the exposure is classified as ‘consider’, 
PEPSE should only be prescribed if there are additional factors that may increase the 
likelihood of transmission (see Box 1).  
o Transmission risk is less than 1 in 10,000 PEPSE is not recommended (2D). 
 
9.1 Source individual is of unknown HIV status  
 
Proactive attempts should be made to establish the HIV status of the source as early as possible 
(2C). It has been shown that in presentations following sexual intercourse with a source of unknown 
HIV status it was possible to contact and test the source in 43.4% of cases and avoid/discontinue 
PEPSE in 40.7%; this resulted in a 31% reduction in cost.  Importantly, this strategy avoids 
unnecessary side effects and toxicity for the individual and facilitates HIV-testing of a high-risk 
group (73, 74). It is therefore recommended that appropriate partner notification is undertaken and 
the source tested for HIV as soon as possible; this should not delay PEPSE initiation.  
 
If the source is from a risk-group or country of high HIV prevalence (prevalence >1%) then PEPSE 
is routinely recommended following receptive anal sex, see Table 3.  
 
9.2 Source individual known to be HIV-positive: 
 
If source individual is known to be HIV-positive attempts should be made at the earliest opportunity 
to determine the HIV viral load, resistance profile and treatment history.  
 
Observational studies have long demonstrated a protective effect of viral suppression on risk of 
transmission (75-77). Then followed the HPTN 052 study, an RCT primarily in heterosexual 
serodifferent couples, which demonstrated a 96% reduction in HIV transmission risk with 
suppressive ART (78). Most recently, the PARTNER Study demonstrated no linked transmissions 
from people with plasma HIV-1 RNA load <200 copies/mL despite a large number of condomless 
sex acts with serodifferent partners (>28,000 acts in heterosexuals and >16,000 acts in MSM) (79).  
We suggest attempts should be made at the earliest opportunity to determine the plasma 
HIV viral load, resistance profile and treatment history of the source (GPP) 
We suggest proactive attempts are made to establish the HIV status of the source (2C) 
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In light of this the recommendation for receptive anal sex with a HIV-positive partner with an 
undetectable plasma HIV VL (confirmed VL<200 copies/ml sustained for >6 months and high 
adherence to ART) has been changed from ‘recommended’ to ‘not-recommended’, see Table 3 
(1B).  
 
The dates and results of the source’s last viral load tests should be confirmed with their clinic for a 
minimum of the last 6 months and recorded in the PEP assessment. If there is any doubt about the 
source’s viral load or adherence to ART then PEPSE should be given as a precaution following 
unprotected anal intercourse.  
 
PEPSE is ‘not-recommended’ following fellatio with ejaculation as we believe the risk is <1/10,000 
(2C). A cohort study demonstrated that after an estimated total of over 19,000 unprotected 
orogenital exposures with an HIV-positive partner no HIV seroconversions occurred (25). Case 
reports of oral transmission exist and modeling studies have estimated a risk of 4/10,000 (12). In 
extreme circumstances such as primary HIV infection and oropharyngeal trauma / ulceration PEP 
can be considered but in general PEP is not recommended.  PEPSE is also not recommended 
following semen splash in the eye as there have been no documented HIV transmissions via this 
route (GPP). Following insertive vaginal intercourse with an HIV-positive partner not on ART, 
PEPSE should be ‘considered’ rather than routinely ‘recommended’ as the risk is <1/1219 (14, 15, 
19) (2C). Again, presence of additional factors in Box 1 should be reviewed and clinician discretion 
applied.  
 
9.3 Needlestick injury in the community   
In general, PEP is not recommended following a community needlestick exposure as it is usually 
not possible to determine: (i) whether the needle has been used and for what purpose; (ii) the HIV 
status of the source and; (iii) the interval between the needle use and the exposure (2D). Once 
blood has dried, HIV becomes non-viable within a couple of hours. In studies where only small 
amounts of blood are in the syringe viable HIV cannot be detected after 24 hours (80). 
 
PEPSE is no longer recommended if the source is on ART with a confirmed and sustained 
(>6 months) undetectable plasma HIV viral load (<200copies/ml) (1B) 
Individuals should be encouraged to attend for formal PEP assessment and verification of 
source's HIV details even when they believe the source has an undetectable HIV viral load 
(GPP) 
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9.4 Human bites  
Requests for PEP following human bites have been reported. In general PEP is not recommended 
following a bite as, although the risk of transmission is unknown, it is likely to be extremely small 
(2D). In the few reported cases of HIV-transmission following a bite the person inflicting the bite had 
advanced HIV with a high plasma viral load, there was blood in the oropharynx from trauma or deep 
wounds were caused by the bite (31, 32). In extreme circumstances PEP could be considered after 
discussion with a specialist. Further guidance regarding the management of human bites is 
available at: http://cks.nice.org.uk/bites-human-and-animal#!scenario:1 
 
9.5 Sexual assault 
It is believed that transmission of HIV is likely to be increased as a result of any trauma following 
aggravated sexual intercourse (anal or vaginal). Clinicians may therefore consider recommending 
PEPSE more readily in such situations, particularly if the assailant is from a high prevalence group 
(81). It is likely that the uptake will be lower in UK settings if the assailant is from a low prevalence 
group after the balance of risks and benefits are discussed with the patient (2D). 
 
9.6 Commercial sex workers 
Historically in Western Europe, HIV prevalence among female sex workers has remained low <1%. 
Prevalence of HIV is also low in Central Europe (1% - 2%) but is higher in Eastern Europe ranging 
between 2.5% and 8% (82). HIV prevalence is greatest in sex workers who inject drugs (82). HIV 
prevalence among male sex workers, reported from 27 countries, was 14% (83). 
 
10. Assessment and initial management: 
 
It is essential that an appropriate risk assessment be performed to enable provision of PEPSE 
according to the recommendations outlined above. A checklist outlining the necessary risk 
assessment for HIV and hepatitis B/C has been created which may be a useful tool in PEP 
consultations, see Appendix B.  At presentation, and prior to administration of PEPSE, the following 
issues, summarized in Box 2, must be discussed with the individual: 
 
Early assessment in a specialist Sexual Health service, including meeting with a counsellor / sexual 
health advisor has been shown to improve rates of adherence and follow-up HIV testing (84, 85). 
We suggest individuals presenting for PEPSE should be encouraged to attend for regular 
sexual health check-ups and are referred to risk-reduction services if appropriate (2C) 
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Individuals presenting for PEPSE are at higher risk of future acquisition of HIV (68) and so should 
be encouraged to attend for future regular sexual health check-ups and considered for referral to 
risk-reduction services and for HIV Pre-Exposure Prophylaxis when this becomes available (2C). 
 
11. Timing of PEPSE: 
 
In a recent study in rhesus monkeys ART was initiated on day 3 following an intrarectal inoculum of 
SIV in rhesus monkeys. This blocked emergence of viral RNA and proviral DNA in peripheral blood, 
lymph nodes and gastrointestinal tract but on discontinuation of ART after 24 weeks, all animals 
experienced viral rebound (86). This supports a maximum 72-hour window of opportunity for PEP; 
every effort should be made to make PEP obtainable as soon as possible after the exposure.  
 
Starter packs are pre-prepared 3-5 day supplies of antiretrovirals; their use enables timely provision 
of PEP, especially out of hours or from emergency care facilities. This ‘starter’ PEPSE regimen can 
be continued or modified at initial review within five days, depending on further information about 
the source’s HIV status, the source’s virus and the patient’s tolerance of the medication (2D). 
 
12. Duration of PEPSE: 
 
The optimal duration of PEP is unknown. However, animal studies and case-controlled studies of 
health-care workers suggests effectiveness of PEP declines if less than 28 days is used (46). If the 
source tests negative on a 4th generation laboratory assay then PEP can be discontinued.  
 
If it is unlikely the source can be contacted for HIV testing, there are no significant comorbidities, no 
baseline blood/urine test abnormalities are predicted and Truvada / raltegravir is used then a 
complete 28 days supply can be prescribed at the first specialist clinic visit (87). In an emergency 
care setting initiation of PEP with a 5-day starter pack remains preferable so that early contact with 
Sexual Health services can be made and STI screening, testing of the source and risk reduction can 
be facilitated.  
We recommend PEPSE should be initiated as soon as possible after exposure, preferably 
within 24 hours, but can be considered up to 72 hours (1D)  
 
We do not recommend giving PEPSE beyond 72 hours (1D) 
 
We recommend that the duration of PEPSE should be 28 days (1D) 
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13. Which medication regimen to use for PEPSE: 
  
In established HIV infection, combination therapy with at least three medications from two 
medication classes is recommended for initial therapy. It is thus recommended, when the risk HIV 
transmission is considered significant, to use a triple agent regimen for PEPSE (1D). Some 
international guidelines do recommend dual-class regimens in selected situations (88, 89). 
 
If there is evidence that the source has a current or past history of treatment failure, the PEPSE 
regimen should be modified in relation to the drug history and/or resistance testing, if available. 
Expert advice should be sought (1D). 
 
13.1 Nucleoside reverse transcriptase inhibitors (NRTI) 
Truvada (a fixed dose combination of tenofovir and emtricitabine) is recommended as the NRTI 
backbone based on efficacy, tolerability, safety and convenience. Tenofovir and emtricitabine 
demonstrate good genital tract and rectal tissue penetration in animal models (reaching peak levels 
within 24 hours of dosing and maintaining high levels for up to seven days) (48) and good male and 
female genital tract penetration in human studies (90); these characteristics may be advantageous 
for PrEP and PEP (48). Phase 3 PrEP studies have demonstrated high efficacy rates for tenofovir 
(TDF) and Truvada in high-risk heterosexuals and MSM (91-94).  
 
Abacavir is not recommended. A hypersensitivity reaction is reported in up to 8% of patients with 
established infection. Although the risk has not been assessed in HIV-negative individuals, it is 
recommended that abacavir be used in exceptional circumstances only. 
 
13.2 Integrase inhibitors (INI) 
Integrase inhibitors are well-tolerated and have all demonstrated at least non-inferior efficacy 
against non-nucleoside reverse transcriptase inhibitors (NNRTI) and protease inhibitors (PI) (95-97). 
Raltegravir (RAL) has been licensed in Europe since 2007. Elvitegravir and dolutegravir are newer 
agents with less post-marketing experience; both are currently more expensive than raltegravir and 
elvitegravir has the added complication of requiring co-administration with cobicistat, a 
pharmacokinetic booster with a similar drug-drug interaction profile as ritonavir. Neither elvitegravir 
We recommend the use of Truvada and raltegravir as the regimen of choice for PEPSE 
(1B) 
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nor dolutegravir has been studied for PEP though both have the advantage of once daily dosing. 
The Writing Committee believes, based on HIV treatment data, that dolutegravir is an acceptable 
alternative for individuals who cannot take raltegravir. 
 
Observational studies assessing raltegravir-emtricitabine-tenofovir as PEP in MSM conclude that it 
is well tolerated, results in high levels of adherence and avoids potential drug-drug interactions (98-
100). In an RCT, a PEP regimen of Truvada plus raltegravir was better tolerated then Truvada plus 
Kaletra (101). 
 
Many clinics across the UK have already switched to using raltegravir in favour of Kaletra in PEP 
regimens since an EAGA statement was released in April 2015: 
https://www.gov.uk/government/publications/eaga-guidance-on-hiv-post-exposure-prophylaxis 
 
13.3 Non-nucleoside reverse transcriptase inhibitors (NNRTI) 
Nevirapine-based PEP is not recommended; almost 10% of individuals experience grade 3 or 4 
hepatotoxicity (102) and serious liver toxicity (requiring transplant) and death have been reported. 
Efavirenz is associated with significant central nervous system side effects, which may be 
deleterious at a time when levels of anxiety are high; there is no data to support its use in PEP. 
There is currently also no data to support the use of etravirine or rilpivirine for PEP. Stevens-
Johnson syndrome has been reported with etravirine (103, 104). 
 
13.4 Protease Inhibitors (PI) 
Drug interactions are still of great concern for prescribers experienced in the management of HIV 
and a challenge for those not experienced in the use of antiretrovirals. One study reports high levels 
of recreational drug use among MSM genitourinary medicine attendees, an additional interaction 
concern (105). 
 
Kaletra (lopinavir/ritonavir co-formulation) was the previously recommended PI for PEP. Kaletra is 
associated with hyperlipidaemia and frequently causes gastrointestinal disturbances (106) 
necessitating the inclusion of anti-diarrhoeal and antiemetic medication in PEP packs. Side-effects 
are frequently reported and associated with non-adherence / discontinuation (107).  
 
Darunavir/ritonavir and atazanavir/ritonavir have been studied as alternatives to Kaletra and are 
both once daily formulations; both were comparable to Kaletra in terms of side-effects and 
discontinuations (107, 108).  
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13.5 CCR5-receptor antagonists 
Maraviroc is well-tolerated and reaches very high levels in the genital tract so its utility for PEP is 
being investigated. One animal study has shown a lack of prophylactic efficacy despite high drug 
concentrations in rectal tissues (109).  
 
An RCT concluded that a PEP regimen of Truvada plus maraviroc is better tolerated than Truvada 
plus Kaletra (101). A study of maraviroc-based PEP in the UK came to similar conclusions (110).  
 
 
13.6 Side effects 
 
Where an individual reports significant current or previous intolerance to one or more PEP agents 
an alternative agent(s) should be considered (2D). 
 
Any antiretroviral medication may have side effects but these are usually mild. When using Truvada 
and raltegravir we recommend that the routine inclusion of anti-emetics or anti-diarrhoeals is not 
necessary; in situations where Kaletra is indicated, routine provision of anti-emetics and anti-
diarrhoeals should be considered – this may not be necessary with other PI and is unnecessary with 
dolutegravir. Where anti-emetics are provided domperidone should be NOT be used with PI due to 
a significant drug-drug interaction with ritonavir (111). 
 
Although proximal renal tubular dysfunction and Fanconi’s syndrome are well reported in HIV-
positive individuals on tenofovir-based ART, these have not been reported in the setting of PEP or 
PrEP to date (92). 
 
Myopathy and rhabdomyolysis have been reported with raltegravir (112) and caution should be 
taken in individuals with a history of these conditions or who are using other medicinal products 
associated with these conditions, for example statins (www.medicines.org.uk/emc/medicine/20484)    
13.7 Interactions 
 
Although raltegravir (and dolutegravir) poses a low risk in-terms of drug-drug interactions, the 
concomitant use of metal cation containing antacids (aluminium / magnesium / calcium antacids) 
and multivitamins should be avoided if possible. Dose-adjustment is required with concomitant 
We recommend that an accurate medication history should be obtained, including the use 
of over the counter medication, vitamins/minerals, herbal remedies and recreational drugs 
before PEPSE is prescribed (1D) 
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rifampicin use. PIs are associated with numerous drug-drug interactions - see Appendix A for details 
on interactions.  
 
14. Monitoring and Follow-up: 
 
PrEP studies support the safety of Truvada in HIV uninfected individuals (92). There have been no 
reports of proximal renal tubular dysfunction in individuals receiving PEP. The randomized control 
trial of raltegravir versus Kaletra PEP (combined with a Truvada backbone) did not report any liver, 
renal or haematological abnormalities in the raltegravir arm (101).  
 
Raltegravir is less commonly associated with transaminitis and hepatic adverse events than 
protease inhibitors (113). The most at risk group of liver dysfunction are those co-infected with 
Hepatitis C (114). 
 
Full blood count monitoring is no longer deemed relevant as it does not affect the choice of regime 
and only a single case report of a transient haematological abnormality has been reported on 
Kaletra-based PEP (115).  
 
Closer monitoring is however recommended if new symptoms develop on PEPSE (e.g. rash, 
jaundice, muscle pain) or if the recipient is pregnant, there is a risk of drug-drug interaction or if 
significant comorbidities such as hepatitis or renal dysfunction exist or if significant abnormalities 
are detected on baseline testing. Creatinine kinase (CK) should be tested if muscle pain develops 
on PEP, particularly on raltegravir-based PEP.  
 
 
Observational studies have found 16.5% of PEP-recipients had an STI at baseline and an additional 
4.1% had an incubating STI diagnosed at 2 weeks (116). As loss to follow-up is common in PEP-
recipients we recommend opportunistic testing at baseline.  
 
We suggest routine blood test monitoring after initiation of raltegravir-based PEPSE is not 
necessary unless clinically indicated or if baseline blood tests are abnormal (2C) 
 
We suggest performing STI testing (based on clinical situation) at baseline as well as at 2 
weeks post exposure (2C) 
 
We recommend follow-up HIV testing at 8-12 weeks post exposure (1C) 
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Several national audits report that the attendance for follow-up HIV testing at 12 weeks is poor (30-
67%) (61-67). Earlier testing at 8-12 weeks post-exposure may improve testing rates. The HIV test 
must be on a 4th generation laboratory assay.  
 
 
In those who do not have immunity to Hepatitis B we suggest offering an ultra-rapid course of 
Hepatitis B vaccination (or Hepatitis B Immunoglobulin if clinically indicated) as per BASHH 
guidelines (117). Individual clinic policies on screening tests for Hepatitis C vary; where there has 
been significant risk a Hepatitis C core-antigen or Hepatitis C RNA will have greater sensitivity at 
the time of follow-up tests 8-12 weeks post exposure (118).  
 
 
15. Special Scenarios: 
 
15.1 Pregnancy 
 
 
Pregnancy is not a contraindication for PEPSE. Indeed if there is a significant risk of infection, and 
this is not prevented, the high viraemia associated with primary infection would lead to a high 
likelihood of intrauterine infection. A thorough risk assessment should be undertaken and expert 
advice should be sought.  
 
The antiretroviral pregnancy registry (http://www.apregistry.com) demonstrates no increase in birth 
defects in women exposed to tenofoviremtricitibine during pregnancy, including 1st trimester 
exposures (APR category B). 
 
There are insufficient reports of raltegravir exposure during pregnancy for it to be catergorised in the 
APR and its use in pregnancy is currently not advised in the SPC (112). Expert opinion from the 
 
We recommend pregnancy testing in women considering PEPSE (1D) 
 
We suggest pregnancy should not alter the decision to start PEPSE (2D) 
 
Women must be counselled that antiretrovirals used for PEPSE are unlicensed in pregnancy 
and risks / benefits must be carefully discussed (1D) 
We suggest offering an ultra-rapid course of Hepatitis B vaccination if clinically indicated 
and the individual has no immunity at baseline (GPP) 
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guideline-working group found raltegravir benefits to outweigh the risks. Kaletra is poorly tolerated in 
pregnancy and is itself not without risk. Use of antiretroviral medication already characterised on the 
APR may be preferred by clinician or the patient. 
 
15.2 Skin rash or flu-like symptoms during or after PEPSE 
Individuals experiencing a skin rash or flu-like illness while or after taking PEPSE should be advised 
to attend for urgent review to exclude an HIV seroconversion (2D).  
 
15.3 Discontinuation or missed doses of PEPSE  
Individuals missing doses of PEPSE should be counselled according to the number of missed 
doses and the time elapsed from the last administered dose. Persistence of PEP medications at 
therapeutic levels will depend on the pharmacokinetic properties of the individual agents used.  
 
The half-life of raltegravir is relatively short (9 hours) such that predicted levels of this agent will be 
sub-therapeutic 18 hours after a missed dose and largely undetectable by 45 hours. Truvada 
plasma half-life is 12-18 hours according to the Summary of Product Characteristics (119) but were 
longer in a recent study: 31 and 37 hours for tenofovir and emtricitabine, respectively (120). 
Tenofovir and emtricitabine are activated intracellularly and the median intracellular half-lives are 
approximately 150-160 hours (120, 121); and 39 hours (120), respectively. Recommendations on 
whether and when to discontinue PEP after missed doses is largely empirical, based on biological 
and pharmacological rationales as well as expert opinion (see Table 6). 
 
If discontinuation of PEP (for less than 48 hours since the last missed dose) is related to intolerance 
to one or more ART agents, continue PEP with an alternative agent(s) (see Table 4). 
 
15.4 Further high-risk sexual exposures while on PEPSE 
 
Tenofovir and emtricitabine have been shown to prevent acquisition of HIV infection when used as 
PrEP by MSM (93, 94). Individuals reporting further high-risk sexual exposures while receiving 
PEPSE do not need to extend the course of PEP beyond the initial 28 days. However, should this 
exposure be on the last two days of the course then extending the treatment for 48 hours after the 
last exposure should be advised, as this appears to have been highly effective in the IPERGAY 
study with treatment before and after exposure (2B) (94).  
In the event of a further high-risk sexual exposure on the last two days of the PEPSE 
course PEP should be continued for 48hours after the last high-risk exposure (2B) 
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15.5 Management of individuals who repeatedly present for PEPSE or with 
ongoing high-risk behaviour.  
 
There had been little evidence of repeated PEPSE use (59, 68) perhaps due to historically poor 
tolerability of prescribed regimens. However, in the PROUD study some particularly high-risk 
subpopulations had high repeat PEPSE usage and, despite this, a high incidence of HIV acquisition 
(likely due to ongoing risk behaviour which may or may not be covered by PEPSE). 
 
Attending for PEP could be an ideal opportunity to refer individuals for PrEP if it becomes routinely 
available (under consideration by specialist commissioners at the time of guideline preparation) 
(122). Until then, it is recommended that repeated attenders be considered for repeat courses of 
PEPSE on each occasion according to their risk of HIV acquisition. Provision of PEPSE should be 
fully integrated with advice and counselling around safer sex strategies (1C). It is recommended that 
in light of the NICE (2007) recommendations (https://www.nice.org.uk/guidance/ph3) these repeat 
attenders are offered one-to-one structured discussions around a model of behaviour change theory 
which can address factors that can help reduce risk-taking and improve self-efficacy and motivation. 
 
15.6 Management of those with a positive HIV test at baseline or shortly after 
initiating PEPSE: 
HIV testing is mandatory prior to, or shortly after, commencing PEPSE (1A) since undiagnosed HIV 
infection would significantly alter the risk–benefit balance of short-course ART.  
 
Service providers may obtain rapid results through point-of-care tests (POCTs), although caution 
must be given to the higher possibility of both false-positive results, and, in early infection, false-
negative. If a POCT is reactive, a 4th generation serological test should be sent urgently and expert 
advice sought prior to initiating PEP. 
 
 
We recommended that repeat attenders meet with a health Sexual Health Adviser and/or 
psychologist and provision of PEPSE is fully integrated into counselling around safer sex 
strategies (1C)  
If the HIV test is positive after PEPSE has already been initiated we recommend 
continuing PEPSE pending review by an HIV specialist (GPP) 
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If the 4th-generation HIV test is positive after PEP has already been initiated we recommend 
continuing PEP pending review by an HIV specialist. Acute HIV diagnosis after PEPSE initiation 
represents a unique opportunity for very early ART and the potential benefits that entails (123). 
Furthermore, stopping ART in the context of acute infection may result in significant viral rebound 
which could increase the risk of onward transmission (124).  
 
16. PEPSE Service Provision: 
 
For PEPSE to be maximally effective 24-hour access should be available. Local policies and 
pathways must be established to enable this within a geographical network. Emergency medicine 
and urgent care providers will therefore be expected to assume significant responsibility for PEPSE 
provision. Necessary support and training should be provided by local departments with expertise, 
such as genitourinary (GU) medicine, HIV medicine, infectious diseases or virology/ microbiology 
departments. The training issues are essentially those outlined comprehensively in the DH/EAGA 
guidance on HIV PEP (1, 125). 
 
Individuals receiving PEPSE from an emergency or urgent care service should be seen as early as 
possible by a clinic experienced in the management of ART and HIV testing. PEPSE should not be 
withheld until such expertise is available. In situations where early referral to an experienced team is 
not feasible, access to advice from an experienced HIV clinician or team is essential. It is 
recommended that local policies should include 24-hour access to advice from an experienced HIV 
clinician, particularly for complex cases (1D). 
 
17. Awareness of PEPSE: 
It is important that individuals at risk of acquiring HIV are aware of PEPSE, such as those in 
serodifferent couples or MSM. Levels of awareness of PEPSE are low amongst MSM in London 
(126-128) and in a cohort of MSM in Australia, those who were PEP-aware sought PEPSE only for 
a minority of high-risk exposures (68). Whether or not an individual seeks PEP may be related to 
whether the episode was ‘unusual’ or a ‘one off’ and influenced by factors such as characteristics of 
the sexual partner(s), venue and the use of alcohol and/or recreational drugs (129).   
 
Individuals at risk of HIV should be provided with information regarding indications for, and timing of, 
PEPSE as well as other proven risk-reduction strategies, see Appendix B. Community based 
For PEPSE to be maximally effective 24-hour availability is recommended (1C) 
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organisations will have a large part to play in providing this information. Consideration should be 
given to provision of 24-hour helpline access to enable individuals to establish whether presentation 
to hospital services for PEPSE is appropriate (2D). SARCs should ensure that clients and police 
officers are aware of PEP, and the need for a risk assessment of HIV transmission in each case. 
 
In a UK cohort of people living with HIV overall fewer than half were aware of PEPSE (MSM 65.8% 
vs. heterosexual 39.1%) (127, 130). PEPSE should be proactively discussed with individuals 
diagnosed with HIV infection, particularly if in a serodifferent relationship, reporting frequent partner 
change or condomless sexual intercourse (GPP).  
 
18. Cost-effectiveness 
There are no conclusive data regarding the cost-effectiveness of PEPSE. It has been argued that 
the cost of providing PEP may be effectively spent on other prevention initiatives (131). However, 
while the medication cost of a full 28-day course of PEP (with Truvada and raltegravir) is 
approximately £800.14 (BNF price May 2015), the lifetime costs of treatment for an HIV-positive 
individual are estimated to be approximately £360,000 (132). A retrospective cost analysis of the 
San Francisco PEPSE programme showed it to be cost-effective for high-risk exposures and 
potentially cost-saving after receptive anal intercourse in MSM (133). Subsequent modelling utilising 
data from several USA cities (134) and Australia (135) suggests similar cost-effectiveness if PEPSE 
is targeted to high-risk exposures consistent with these guidelines. This is in general accordance 
with a review by the Health Technology Assessment (136). A 28-day course of PEP could be 
substantially less expensive with the use of generic medications available now or in the future. 
 
19. Surveillance on the use of PEPSE: 
Since January 2011 all episodes of PEPSE in England have been reported through the GUMCAD 
system (https://www.gov.uk/government/statistics/sexually-transmitted-infections-stis-annual-data-
tables). Reported PEPSE use has risen annually, particularly amongst MSM. Despite this HIV 
incidence has risen in MSM over the same time period and other evidence-based strategies must 
be advocated.  
 
20. Qualifying statement: 
The recommendations in this guideline may not be appropriate for use in all clinical situations. 
Decisions to follow these recommendations must be based on the professional judgment of the 
clinician and consideration of individual patient circumstances and wishes. It should be 
acknowledged that use of any antiretroviral agent in this setting is an unlicensed indication. All 
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possible care has been undertaken to ensure the publication of the correct dosage and route of 
administration. However, it remains the responsibility of the prescribing physician to ensure the 
accuracy and appropriateness of the medication they prescribe. 
 
21. Applicability: 
The provision of PEPSE requires consideration of appropriate pathways of care between Sexual 
health/HIV clinicians and those providing emergency/primary care, including SARCs, in order to 
ensure PEPSE is administered in a timely and appropriate fashion. This will require local 
interpretation of this guideline and will most likely involve a degree of organizational change and 
pro-vision of additional resources. 
  
22. Auditable outcome measures: 
  
1. Proportion of PEPSE patients having a baseline HIV test: aim 100% within 72 hours of 
presenting for PEPSE  
 
2. Proportion of PEPSE prescriptions that fit within recommended indications: aim 90%  
  
3. Proportion of PEPSE prescriptions administered within 24 hours of risk exposure: aim 90%  
  
4. Proportion of individuals completing 4-week course of PEPSE: aim 75%  
 
5. Proportion of individuals seeking PEPSE undergoing testing for STIs: aim 90% 
  
6. Proportion of individuals completing 8-12 week post-exposure HIV antibody/antigen test: aim 
75%.  
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Table 1: Estimated HIV prevalence (diagnosed and undiagnosed infection) in  
adults aged 15-59 years in the UK in 2014 
 
 
 
  HIV prevalence (%) 
Population group (aged 15-59 years)‡ Men Women 
      
Men who have sex with men (MSM)† 
  
UK 5.9 – 
London 12.5 – 
Brighton 13.7  
Manchester 8.6  
Elsewhere in the UK 3.8 – 
Heterosexuals 
  
Black African Ethnicity 4.1 7.1 
Non Black African Ethnicity 0.06 0.06 
Injecting drug users (IDU) 0.67 - 1.1 0.67 – 1.1 
  
 
‡
 These data are for England and Wales only 
†The prevalence of HIV among MSM varies across the UK and is higher in metropolitan areas with 
large MSM populations6,7 
Prevalence estimates were obtained at:  
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/401662/2014_P
HE_HIV_annual_report_draft_Final_07-01-2015.pdf (page 8, figure 1)  
 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/475712/Shooting_U
p_2015_FINAL.pdf 
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Table 2 Risk of HIV transmission per exposure from a known HIV-positive  
individual not on ART 
 
 
Type of exposure 
Estimated risk of HIV 
transmission per exposure 
from a known HIV-positive 
individual not on ART 
References 
Receptive anal intercourse 1 in 90  (10-16) 
      Receptive anal intercourse with ejaculation 1 in 65  (10-17) 
      Receptive anal intercourse no ejaculation 1 in 170  (17) 
Insertive anal intercourse 1 in 666 (10, 12, 13, 18) 
      Insertive anal intercourse not circumcised 1 in 161 (17) 
     Insertive anal intercourse and circumcised 1 in 909 (17) 
Receptive vaginal intercourse 1 in 1000 (10, 15, 19-25) 
Insertive vaginal intercourse 1 in 1,219 (14, 15, 19-25) 
Semen splash to eye <1 in 10,000 (26) 
Receptive oral sex (giving fellatio) < 1 in 10,000 (13, 20, 25, 27) 
Insertive oral sex (receiving fellatio) < 1 in 10,000 (12, 25) 
Blood transfusion (one unit) 1 in 1 (28) 
Needlestick injury 1 in 333 (27, 29, 30) 
Sharing injecting equipment (includes 
chemsex) 
1 in 149 (26) 
Human bite < 1 in 10,000 (31, 32) 
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Box 1: Factors increasing the risk of HIV transmission: 
 
1. A high plasma HIV viral load (VL) in the source – with each log10 increase in 
plasma HIV RNA the per-act risk of transmission in increased 2.9 fold [95% 
confidence interval (CI) 2.2-3.8] (33). This may be particularly relevant during 
primary HIV infection (20). 
2. Breaches in the mucosal barrier such as mouth or genital ulcer disease and 
anal or vaginal trauma following sexual assault or first intercourse (34, 35). 
3. Menstruation or other bleeding – theoretical risk only 
4. Sexually transmitted infections in HIV positive individuals not on ART (36, 37) 
or HIV negative individuals with genital ulcer disease (38). 
5. Ejaculation - Among a community cohort of men who have sex with men 
(MSM) the risk of HIV acquisition per episode of unprotected receptive anal 
intercourse with and without ejaculation was estimated to be 1.43% (95% 
confidence interval [CI] 0.48–2.85) and 0.65% (95% CI 0.15– 1.53), respectively 
(17). 
6. Non-circumcision - circumcision has been shown to significantly reduce HIV 
acquisition among heterosexual men in high prevalence countries (39-42). In 
2008 a meta-analysis of observational studies in MSM suggests circumcision 
has little impact upon HIV acquisition (43). However, since then the risk of HIV 
acquisition per episode of unprotected insertive anal intercourse in circumcised 
men was estimated to be 0.11% (95% CI 0.02–0.24) versus 0.62% (95% CI 
0.07–1.68) in uncircumcised men in a community cohort of MSM in Australia 
(17). 
7. Discordant HIV viral load in the genital tract - In general, the genital tract 
viral load is undetectable when the plasma viral load is undetectable. When this 
is not the case the viral load in the genital tract is usually low (44, 45).   
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Table 3: Summary table of PEPSE prescribing recommendations 
 
 
 
  
 Source HIV status 
HIV positive Unknown HIV status 
 
HIV VL unknown / 
detectable 
(>200copies/ml) 
 
HIV VL undetectable 
(<200copies/ml)  
  
From high prevalence 
country / risk-group 
(e.g. MSM) * 
 
From low prevalence 
country / group 
Receptive anal sex Recommend Not recommended% 
Provided source has confirmed 
HIV VL<200c/ml for >6 months  
Recommend Not recommended 
Insertive anal sex Recommend Not recommended Consider† Not recommended 
Receptive vaginal sex Recommend Not recommended Consider† Not recommended 
Insertive vaginal sex Consider& Not recommended Consider† Not recommended 
Fellatio with 
ejaculation‡ 
Not recommended Not recommended Not recommended Not recommended 
Fellatio without 
ejaculation‡ 
Not recommended Not recommended Not recommended Not recommended 
Splash of semen into 
eye 
Not recommended Not recommended Not recommended Not recommended 
Cunnilingus Not recommended Not recommended Not recommended Not recommended 
Sharing of injecting 
equipment** 
Recommended Not recommended Consider Not recommended 
Human bite§ Not recommended Not recommended Not recommended Not recommended 
Needlestick from a 
discarded needle in 
the community 
          Not recommended Not recommended 
 
* High prevalence countries or risk-groups are those where there is a significant likelihood of the source individual being HIV-
positive. Within the UK at present, this is likely to be MSM, IDUs from high-risk countries (see ** below) and individuals who 
have immigrated to the UK from areas of high HIV prevalence, particularly sub-Saharan Africa (high prevalence is >1%). HIV 
prevalence Country specific HIV prevalence can be found in UNAIDS Gap Report:  
http://www.unaids.org/en/resources/campaigns/2014/2014gapreport/gapreport 
 
% The source’s viral load must be confirmed with the source’s clinic as <200c/ml for >6 months. Where there is any 
uncertainty about results or adherence to ART then PEP should be given after unprotected anal intercourse with an HIV-
positive person 
 
† More detailed knowledge of local prevalence of HIV within communities may change these recommendations from consider 
to recommended in areas of particularly high HIV prevalence.  Co-factors in Box 1 that influence the likelihood of 
transmission should be considered 
 
& Co-factors in Box 1 that influence the likelihood of transmission should be considered 
 ‡ PEP is not recommended for individuals receiving fellatio i.e. inserting their penis into another’s oral cavity. For individuals 
giving fellatio PEP is not recommended unless co-factors 1 & 2 in Box 1 are present e.g HIV seroconversion and oropharyngeal 
trauma / ulceration, see notes in guideline above  
 
**HIV prevalence amongst IDUs varies considerably depending on country of origin and is particularly high in IDUs from Eastern 
Europe and central Asia. Region-specific estimates can be found in the UNAIDS Gap Report 
http://www.unaids.org/sites/default/files/media_asset/05_Peoplewhoinjectdrugs.pdf 
  
§ A bite is assumed to constitute breakage of the skin with passage of blood. See notes in guideline above about extreme 
circumstances where PEP could be considered after discussion with a specialist 
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Box 2: Items to discuss with individual initiating PEPSE: 
1. The rationale for PEPSE 
2. The lack of conclusive data for the efficacy of PEPSE 
3. The potential risks and side-effects of PEPSE 
4. The arrangement for early follow-up with an HIV/GU medicine clinician 
5. Pre-test discussion and HIV test (4th generation laboratory test) 
6. The need to continue PEPSE for 28 days if the baseline result is negative 
7. The need to have a follow-up HIV test 8-12 weeks post-exposure 
8. The need for safer sex for the following two months 
9. Emergency contraception should be discussed if relevant 
10. Coping strategies, assessment of vulnerabilities and social support 
11. For patients concerned about sexual risk-taking health Sexual Health Advisers can offer 
ongoing risk reduction work or referral to psychology  
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Table 4. Recommended combinations for PEP 
 
 
 NRTI Backbone (2 medications) Third agent 
 
Recommended 
combination 
 
 
Truvada&  one tablet once daily 
(tenofovir disoproxil fumarate 
245mg, emtricitabine 200mg)  
 
Raltegravir 400mg every 
12 hours* 
 
 
Alternative 1# 
 
 
Combivir (Zidovudine 250mg 
twice daily plus lamivudine 150mg 
twice daily) 
Protease inhibitor 
Kaletra (lopinavir 200mg, 
ritonavir 50mg**) Two 
tablets twice daily  
OR 
Darunavir 800mg once 
daily + ritonavir 100mg** 
once daily 
OR 
Atazanavir 300mg once 
daily + ritonavir 100mg** 
once daily 
OR 
Dolutegravir 50mg once 
daily$ 
 
& Truvada is the preferred agent in chronic hepatitis B virus infection 
 
* Antacids and multivitamins (products containing m tal cations e.g. magnesium / aluminium, which can 
chelate and reduce the absorption of raltegravir) should be avoided where possible during PEP, see 
appendix A. An alternative non-interacting medication may be considered. See appendix A about co-
administration of rifampicin   
# Combivir may be preferred to Truvada in patients with abnormal renal function at baseline. Lamivudine 
may require dose-adjustment depending on renal function.    
**Significant drug-drug interactions can occur with boosted protease inhibitors, seek expert advice from 
a HIV specialist pharmacist, local medicines and poisons information centre or use the website 
www.hiv-druginteractions.org 
 
$At the time of publication there are no data on the use of dolutegravir as PEP but it is anticipated to be 
well-tolerated 
 
Swallowing difficulty - Truvada can be disintegrated in 100 ml of water or orange juice and taken 
immediately. Kaletra can be used as an alternative to raltegravir and is commercially available as an 
oral solution; the recommended dosage is 5ml twice daily with food. 
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Table 5: Recommended monitoring during PEP course and follow-up 
 
 
 Baseline 14 days 8-12 weeks post-
exposure 
HIV 俶  俶 
Hep B sAg  
(if no history of 
vaccination) 
俶  俶 
only if not immune 
 
Syphilis, 
Hep C, Hep 
B immunity 
As per local clinic policy or BASHH guidelines 
http://www.bashh.org/BASHH/Guidelines/Guidelines/BASHH/Guidelines/Guidelines.
aspx 
STI testing  
(as appropriate 
per local clinic 
policy) 
俶 
 
俶 If further UPSI has taken place 
Creatinine  俶 Only if abnormalities at baseline  
Alanine 
transaminas
e (ALT) 
俶 Only if abnormalities at baseline, Hep B/C co-
infected or on Kaletra 
 
Urinalysis or 
uPCR 
俶 Only if abnormalities at baseline 
if abnormalities at baseline or 2 
weeks 
Pregnancy 
test 
俶 If appropriate If appropriate 
CK  Only if symptomatic of 
myositis 
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Table 6: Guidance on missed doses of PEPSE (2D) 
 
 
Scenario Recommendation Comments 
<24 hours elapsed 
since last dose 
Take missed doses 
immediately and subsequent 
doses at usual time 
Reinforce importance of adherence and re-evaluate 
motivation to continue PEP 
24-48 hours elapsed 
since last dose 
Continue PEPSE Reinforce importance of adherence and re-evaluate 
motivation to continue PEP 
>48 hours since last 
dose 
Recommend stop PEPSE  
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Table 7. Reported use of PEPSE via GUMCAD 2011-2013 
 
 
   2011              2012            2013 
Male Heterosexual 677 974 988 
MSM 2,386 3,763 4,237 
Women heterosexual 723 940 982 
Women who have sex with women 20 24 22 
Total 3,975 5,862 6,410 
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APPENDIX A 
 
POTENTIAL FOR DRUG–DRUG INTERACTIONS 
When prescribing PEP it is essential to ensure that the potential for drug–drug 
interactions is considered, therefore an accurate patient medication history should be 
reconciled. Clinicians are advised to liaise with a HIV specialist pharmacist and/or 
use Liverpool Drug Interaction website (http://www.hiv-druginteractions.org) for this 
purpose. Examples of relevant drug–drug interactions between raltegravir and other 
medications are shown in Appendix A.  Consideration should be given to the use of 
over-the-counter and recreational drugs.  
 
DRUG-DRUG INTERACTIONS WITH TRUVADA 
There are no significant drug-drug interactions although caution should be applied 
when Truvada is co-administered with other potentially nephrotoxic agents. 
Enhanced renal monitoring may be warranted in this situation. 
 
DRUG–DRUG INTERACTIONS WITH RALTEGRAVIR 
In vitro studies indicate that raltegravir is not a substrate of cytochrome P450 (CYP) 
enzymes, does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, 
CYP2D6 or CYP3A, does not induce CYP3A4 and does not inhibit P-glycoprotein-
mediated transport. Based on these data, raltegravir is not expected to affect the 
pharmacokinetics of medicinal products that are substrates of these enzymes or P-
glycoprotein. 
 
Co-administration of raltegravir with aluminium and magnesium antacids resulted in 
reduced raltegravir plasma levels. Cationic complexation results in reduced 
absorption of raltegravir therefore co-administration of raltegravir with antacids and 
multivitamins should be avoided where possible during PEP. Caution and 
appropriate advice as outlined in appendix A should be given if the patient is taking 
calcium or iron preparations.  
 
Raltegravir is eliminated mainly by metabolism via a UGT1A1-mediated 
glucuronidation pathway. Given that raltegravir is metabolised primarily via UGT1A1, 
caution should be used when co-administering raltegravir with strong inducers of 
UGT1A1 (e.g. rifampicin). Rifampicin reduces plasma levels of raltegravir; the impact 
on the efficacy of raltegravir is unknown. However, if co-administration with rifampicin 
is unavoidable, a doubling of the dose of raltegravir can be considered in adults. The 
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impact of other strong inducers of drug metabolising enzymes, such as phenytoin 
and phenobarbital, on UGT1A1 is unknown. Less potent inducers (e.g., efavirenz, 
nevirapine, etravirine, rifabutin, glucocorticoids, St. John's wort, pioglitazone) may be 
used with the recommended dose of raltegravir. 
 
The table below outlines the potential drug–drug interactions with raltegravir and 
commonly used medication, or where interactions are significant. Please seek advice 
from a specialist HIV pharmacist and/or use Liverpool Drug Interaction website 
http://www.hiv-druginteractions.org  
 
Medication Problem Advice 
Metal Cations 
Aluminium/magnesium hydroxide and 
calcium carbonate antacids 
 
Co-administration of raltegravir with antacids 
resulted in reduced raltegravir plasma levels. 
Co-administration of raltegravir with antacids is NOT 
recommended. 
Stop antacid and prescribe PPI/H2 antagonist if 
required 
Calcium supplements 
Caution is recommended as raltegravir 
concentrations may be reduced 
No dose adjustment is required but should be taken 
well separated in time from the administration of 
raltegravir (At least 4 hours after or 6 hours before). 
 
Iron supplements 
 
 
The effect of cationic complexation resulting in 
reduced absorption cannot be excluded 
 
Iron supplements should be taken well separated in 
time from the administration of raltegravir (At least 4 
hours after or 6 hours before). 
 
Multi-vitamins 
Multivitamin preparations may contain 
polyvalent cations. The effect of cationic 
complexation resulting in reduced 
absorption cannot be excluded. 
Caution is recommended as raltegravir 
concentrations may be reduced. 
Multivitamins should be taken well separated in time 
from the administration of raltegravir (At least 4 hours 
after or 6 hours before). Or ideally avoid if possible. 
Anticonvulsants 
 
Carbamazepine 
Coadministration has not been studied but could 
potentially decrease raltegravir concentrations as it 
is mainly glucuronidated by UGT1A1 and in vitro 
data suggest that carbamazepine induces UGT1A1 
No dose adjustment recommended 
 
Phenobarbitone/phenytoin 
 
The impact of phenobarbital on UGT1A1 is 
unknown. 
No dose adjustment recommended 
Antimicrobials 
 
Rifabutin 
Coadministration of raltegravir (400 mg twice daily) 
and rifabutin (300 mg once daily) increased 
raltegravir AUC (19%) and Cmax (39%), but 
decreased Ctrough (20%).  
These changes were not deemed clinically significant 
and no dose adjustment is required. 
Rifampicin 
raltegravir AUC ↓ 40 %  
raltegravir C12hr ↓ 61 %  
raltegravir Cmax ↓ 38 %  
(UGT1A1 induction) 
Rifampicin reduces plasma levels of raltegravir. If co-
administration with rifampicin is unavoidable, a 
doubling of the dose of raltegravir to 800mg every 
12 hours can be considered. NB additional quantities 
of raltegravir will be required to cover until next review.  
H2 Blockers and Proton pump inhibitors 
 
Omeprazole 
raltegravir AUC ↑ 37 %  
raltegravir C12 hr ↑ 24 %  
raltegravir Cmax ↑ 51 % 
No dose adjustment required for raltegravir 
 
Famotidine 
raltegravir AUC ↑ 44 %  
raltegravir C12 hr ↑ 6 %  
raltegravir Cmax ↑ 60 % 
No dose adjustment required for raltegravir 
HCV ANTIVIRALS 
 
Bocepravir 
Coadministration of raltegravir (400 mg every 12 
hours) and boceprevir (800 mg three times daily) 
increased raltegravir AUC and Cmax by 4% and 
11%, but decreased C12h by 25%. Boceprevir AUC, 
Cmax and C8h decreased by 2%, 4% and 26% 
respectively 
Increased clinical and laboratory monitoring for HCV 
suppression is recommended 
 
Daclatasavir 
Coadministration has not been studied but based on 
metabolism and clearance a clinically significant 
interaction is unlikely.  
No dose adjustment of daclatasvir or raltegravir is 
required 
 
Ledipasvir/Sofosbuvir 
Coadministration of raltegravir and ledipasvir 
decreased raltegravir AUC and Cmax by 15% and 
18%, whereas coadministration of raltegravir and 
No dose adjustment of ledipasvir/sofosbuvir or 
raltegravir is required 
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sofosbuvir decreased raltegravir AUC and Cmax by 
27% and 43%. When raltegravir is given with 
ledipasvir/sofosbuvir it is not known whether the 
decrease in raltegravir will be greater.  
 
Ombitasvir/paritaprevir/ritonavir 
 Raltegravir can be administered with 
ombitasvir/paritaprevir/ritonavir and no dose alteration 
is required. 
Ombitasvir/paritaprevir/ritonavir + 
dasabuvir 
 Raltegravir can be administered with 
ombitasvir/paritaprevir/ritonavir + dasabuvir and no 
dose alteration is required 
 
Simeprevir 
Coadministration of raltegravir (400 mg twice daily 
for 7 days) and simeprevir (150 mg once daily for 7 
days) was studied in 24 subjects. Simeprevir Cmax, 
AUC and Cmin decreased by 7%, 11% and 14%, 
respectively. Raltegravir Cmax, AUC and Cmin 
increased by 3%, 8% and 14%, respectively.  
No dose adjustment is required. 
 
Sofosbuvir 
Coadministration of sofosbuvir and raltegravir (400 
mg once daily) decreased raltegravir Cmax, AUC 
and Cmin by 43%, 27% and 5%, respectively. 
Sofosbuvir Cmax and AUC decreased by 13% and 
5%, whereas GS-331007 Cmax and AUC increased 
by 9% and 3%.   
No dose adjustment of sofosbuvir or raltegravir is 
required when sofosbuvir and raltegravir are used 
concomitantly. 
 
Telaprevir 
Based on preliminary data, the combination of 
telaprevir and raltegravir did not result in a clinically 
significant interaction.  
If co-administered, no dose adjustment is required. 
Miscellaneous 
Antidepressants (including St John's 
Wort) 
 Clinically significant interactions unlikely 
Antipsychotics/neuroleptics:  Clinically significant interactions unlikely 
Gemfibrozil Could potentially increase raltegravir levels Monitor for side effects 
Methadone  No dose adjustment required for raltegravir or 
methadone 
Midazolam midazolam AUC ↓ 8 %  
midazolam Cmax ↑ 3 % 
No dose adjustment required for raltegravir or 
midazolam 
Oral/emergency contraceptives and 
contraceptive patch 
Ethinyl Estradiol AUC ↓ 2 %  
Ethinyl Estradiol Cmax ↑ 6 %  
Norelgestromin AUC ↑ 14 %  
Norelgestromin Cmax ↑ 29 % 
No dosage adjustment required for raltegravir or 
hormonal contraceptives (estrogen- and/or 
progesterone-based).  
 
DRUG-DRUG INTERACTIONS WITH DOLUTEGRAVIR 
Since dolutegravir is an alternative agent detailed discussion of pharmacokinetics 
and drug-drug interactions is not included here. Like raltegravir, dolutegravir interacts 
with magnesium/aluminium-containing antacids - these should be taken well 
separated in time from the administration of dolutegravir. Other significant 
interactions include enzyme-inducing anti-epileptics and metformin; we advise use of 
The Liverpool Drug Interactions website to check interactions with all concomitant 
medication. 
 
DRUG-DRUG INTERACTIONS WITH PROTEASE INHIBITORS 
As these are alternatives for PEP detailed discussion of pharmacokinetics and drug-
drug interactions is not included here. Ritonavir is associated with numerous drug-
drug interactions and St John’s Wort is contra-indicated with all PI; we advise use of 
The Liverpool Drug Interactions website to check interactions with all concomitant 
medication.  
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         APPENDIX B 
PEPSE CHECKLIST               For further information see complete 2015 BASHH HIV Post-Exposure Prophylaxis guideline 
This checklist is an aid to clinical practice only and does not replace local expert advice where indicated 
CLINIC ID DOB DATE  
PREVIOUS TESTING 
Test Result Date Test Result  Date 
HIV   HBcAb   
Syphilis   HBsAg   
Hepatitis A IgG   HBsAb   
Hepatitis C       
BASELINE TESTING 
Test Result Date Test Result  Date 
HIV   STI screen   
Syphilis   Renal   
Hep A IgG (MSM 
non-immune) 
  Liver   
HBcAb  
(no history of vaccination) 
  Urinalysis / 
uPCR 
  
HBsAb  
(history of vaccination) 
  Pregnancy test 
(if indicated)  
  
Hep C IgG       
CHARACTERISTICS OF EXPOSURE 
Date of exposure Time of exposure Hours since exposure 
Sexual Assault                  yes     ܆no   ܆ 
Condom                           used    ܆                      not used   ܆                      broke  ܆                   fell off   ܆ 
Receptive anal sex                      ܆ejaculation  ܆withdrawal  ܆ 
Insertive anal sex                        ܆                 circumcised   ܆        uncircumcised  ܆ 
Receptive vaginal sex                 ܆ 
Insertive vaginal sex                   ܆             circumcised   ܆        uncircumcised  ܆ 
Fellatio (giving)                           ܆ejaculation   ܆withdrawal   ܆ 
Semen splash in eye                  ܆ 
Sharing injecting equipment       ܆ 
Human bite                                 ܆  
CHARACTERISTICS OF SOURCE 
Source details Source risk factor HIV status HIV details BBV details 
No. of partners  MSM                      ܆ Positive       ܆ No /  Unknown ART   ܆ Hep B +   ܆ 
Male                 ܆ High prev. country ܆
Specify 
Suspected  ܆ On ART                      ܆ Hep C +   ܆ 
Female             ܆ Unknown    ܆ HIV viral load             c/ml             Date 
Transgender    ܆ Injecting drug use  ܆  HIV viral load             c/ml             Date  
PEP ASSESSMENT        Date                                      Time                                                             Location 
Comorbidities  PEP recommended?            yes  ܆               no  ܆ 
Medication history (including over the counter and herbal) Hep B vaccine required?      yes  ܆               no  ܆ 
Drug allergies Contraception required?       yes  ܆               no  ܆ 
Adherence concerns Sexual Health Adviser          yes  ܆               no  ܆ 
PEP regimen prescribed Dose Frequency Duration 
    
     
DISCUSSION POINTS WITH PATIENT 
The ART is unlicensed for use as PEP Side-effects 
PEP is not 100% effective Emergency contact details 
Possible risks and benefits Safe sex 
Adherence and missed doses rules Risk reduction around alcohol and drugs (if indicated)  
Follow up location  Follow up time and date 
Clinician name                                                                  Signature  
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APPENDIX C 
 
LEVELS AND GRADING OF EVIDENCE 
 
Strength of recommendation Grading of evidence 
 
1 Strong recommendation 
 
For patients – most people in this 
stuation would want the 
recommended course of action and 
only a small proportion would not 
For clinicians – Most people should 
receive the intervention 
 
 
 
A. High quality evidence 
Benefits clearly outweigh the risk and burdens or vice versa 
Consistent evidence from well performed randomised controlled trials or 
overwhelming evidence of some other form. Further research is unlikely 
to change our confidence in the estimate of benefit or risk. 
 
 
B. Moderate quality evidence 
Benefits clearly outweigh risk and burdens or vice versa 
Evidence from randomised controlled trials with moderate limitatons 
(inconsistent results, methodological flaws, indirect or imprecise) or very 
strong evidence from some other research design. Further research may 
impact on our confidence in the estimate of benefit or risk.  
 
2. Weak recommendation 
 
For patients – Most people in this 
situation would want the suggested 
course of action, but many would 
not.  
For clinicians – Examine the 
evidence or a summary of the 
evidence yourself ans be prepared to 
discuss that evidence with patients, 
as well as theor values and 
preferemces 
 
 
 
C. Low-quality evidence 
Benefits appear to outweigh the risk and burdens or vice versa 
Evidence from observational studies, unsystematic clinical experience or 
from RCTs with serious flaws. Any estimate of effect is uncertain.  
 
D. Very low quality evidence 
Benefits appear to outweigh the risk and burdens or vice versa 
Evidence limited to case studies 
 
GPP. Good practice point 
Recommended best practice based on the experience of the 
guideline working group 
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